阿立哌唑与利培酮对首发精神分裂症患者认知功能及社会功能的影响
|
摘要
目的评价阿立哌唑与利培酮对首发精神分裂症患者认知功能及社会功能的影响。方法选择我院2016年7月～2018年6月收治的精神分裂症患者60例为本次研究对象,按照随机数字表法分为对照组30例与观察组30例。对照组给予利培酮治疗,观察组给予阿立哌唑治疗,对比两组患者认知功能及社会功能改善情况。结果PANSS情况:治疗前两组患者的PANSS评分比较,差异无统计学意义(P>0.05),第12周时观察组优于对照组,差异存在统计学意义(P<0.05);第12周与治疗前比较,观察组组内评分存在统计学意义(P<0.05);MCCB情况:治疗前两组患者的TMTA、SC、AN、NAB-Mazes数据比较,差异无统计学意义(P>0.05),第12周时除NAB-Mazes外其余因子观察组优于对照组,差异有统计学意义(P<0.05);PSP情况:治疗前两组患者的PSP评分比较无统计学意义(P>0.05),第12周时两组患者PSP评分比较,差异无统计学意义(P>0.05);第12周与治疗前比较,两组组内评分均存在统计学意义(P<0.05)。结论阿立哌唑与利培酮用于治疗精神分裂症患者均能有效改善患者的社会功能,但阿立哌唑能够显著改善患者阴性症状与认知功能,值得临床应用与推广。
Objective To evaluate the effects of aripiprazole and risperidone on cognitive function and social function in patients with first-episode schizophrenia. Methods Sixty patients with schizophrenia admitted to our hospital from July 2016 to June 2018 were enrolled in this study. According to the random number table method, 30 patients were divided into the control group and 30 patients were divided into the observation group. The control group was treated with risperidone, and the observation group was treated with aripiprazole. The cognitive function and social function improvement of the two groups were compared. Results PANSS: There was no significant difference in PANSS score between the two groups before treatment(P>0.05). At 12 weeks, the observation group was superior to the control group,and the difference was statistically significant(P<0.05); At week 12, the scores of the observation group were statistically different from those before treatment(P<0.05). MCCB: There were no significant differences in TMTA, SC, AN, and NAB-Mazes between the two groups before treatment(P>0.05). At the 12 th week, the other factors except NAB-Mazes were better in the observation group than in the control group(P<0.05). PSP: There was no significant difference in PSP score between the two groups before treatment(P>0.05). There was no significant difference in PSP score between the two groups at 12 weeks(P>0.05). At week 12, the scores of both groups were statistically different from those before treatment(P<0.05). Conclusion Both aripiprazole and risperidone can effectively improve the social function of patients with schizophrenia, but aripiprazole can significantly improve the negative symptoms and cognitive function of patients,which is worthy of clinical application and promotion.
Objective To evaluate the effects of aripiprazole and risperidone on cognitive function and social function in patients with first-episode schizophrenia. Methods Sixty patients with schizophrenia admitted to our hospital from July 2016 to June 2018 were enrolled in this study. According to the random number table method, 30 patients were divided into the control group and 30 patients were divided into the observation group. The control group was treated with risperidone, and the observation group was treated with aripiprazole. The cognitive function and social function improvement of the two groups were compared. Results PANSS: There was no significant difference in PANSS score between the two groups before treatment(P>0.05). At 12 weeks, the observation group was superior to the control group,and the difference was statistically significant(P<0.05); At week 12, the scores of the observation group were statistically different from those before treatment(P<0.05). MCCB: There were no significant differences in TMTA, SC, AN, and NAB-Mazes between the two groups before treatment(P>0.05). At the 12 th week, the other factors except NAB-Mazes were better in the observation group than in the control group(P<0.05). PSP: There was no significant difference in PSP score between the two groups before treatment(P>0.05). There was no significant difference in PSP score between the two groups at 12 weeks(P>0.05). At week 12, the scores of both groups were statistically different from those before treatment(P<0.05). Conclusion Both aripiprazole and risperidone can effectively improve the social function of patients with schizophrenia, but aripiprazole can significantly improve the negative symptoms and cognitive function of patients,which is worthy of clinical application and promotion.
引文
[1]王洪艳,曹歆轶,李伟,等.精神分裂症认知康复训练的研究进展[J].国际精神病学杂志,2015,42(2):139-142.
[2]郭建玉,卜晓波,韩彦龙.精神分裂症相关基因遗传学研究进展[J].牡丹江医学院学报,2016,37(4):116-118.
[3]宋丽华,李素水,孙志刚,等.精神分裂症认知障碍和功能预后关系的纵向研究进展[J].国际精神病学杂志,2015,42(5):47-51.
[4]梅力,易正辉.精神分裂症伴发代谢综合征的防治研究进展[J].中国神经精神疾病杂志,2014,40(7):443-446.
[5]董佳丽,常艳玲,黄震,等.新型非典型抗精神病药物的应用及研究进展[J].上海医药,2015,36(7):53-56.
[6]司天梅,杨建中,舒良,等.阳性和阴性症状量表(PANSS,中文版)的信、效度研究[J].中国心理卫生杂志,2004,18(1):45-47.
[7]Stephen R.Marder,Wayne Fenton.Measurement and treatment research to improve cognition in schizophrenia:NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia[J].Schizophrenia Research,2004,72(1):5-9.
[8]Morosini PL,Magliano L,Brambilla L,et al.Development,reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale(SOFAS)to assess routine social funtioning[J].Acta Psychiatrica Scandinavica,2000,101(4):323-329.
[9]严峰,陆峥,周卉.精神分裂症与认知功能障碍及其生物学基础研究[J].世界临床药物,2013,34(11):693-697.
[10]左赛,Linda K.BYRNE,彭代辉,等.症状严重程度比认知缺损更与精神分裂症住院患者的社会功能状况密切相关(英文)[J].上海精神医学,2012,24(2):83-90.
[11]朱叶,方菁,张蓓,等.精神分裂症社会认知功能缺陷的功能影像研究[J].中国临床心理学杂志,2014,22(2):232-239.
[12]何宗岭,黄吉林,李涛,等.首发精神分裂症患者治疗前后认知功能损害的比较[J].中国神经精神疾病杂志,2013,39(7):411-415.
[13]孟美玲,李清伟,盛建华,等.阿立哌唑治疗抗精神病药物所致高催乳素血症的研究进展[J].精神医学杂志,2015,28(3):232-234.
[14]Hikaru H,Yoshimura R,Katsuki A,et al.The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients[J].Journal of Psychiatric Research,2012,46(6):757-761.
[15]王汝展.精神类药物基因组学研究进展[J].精神医学杂志,2016,29(1):47-52.
[16]Riedel M,Schennech-Wolff R,Musil R.Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole,olanzapine,quetiapine and risperidone[J].Human Psychopharmacology,2010,25(2):116-125.
[17]梁静文,许瑞环.精神分裂症患者认知功能障碍的相关基因研究进展[J].精神医学杂志,2017,30(6):465-471.
[18]Ahmed El-Missiry,Amira Elbatrawy,Marwa El Missiry,et al.Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia[J].Journal of Psychiatric Research,2015,70(1):S97-S98.
[19]罗爱军,陈哨,单超.精神分裂症患者认知功能损害特点及非药物治疗方法的研究进展[J].河北医药,2018,40(17):2683-2687.
[20]何孔亮,刘晓林,韦邦贵,等.阿立哌唑与利培酮对精神分裂症后抑郁患者疗效与执行功能的影响[J].安徽医药,2015,19(4):772-774.
[2]郭建玉,卜晓波,韩彦龙.精神分裂症相关基因遗传学研究进展[J].牡丹江医学院学报,2016,37(4):116-118.
[3]宋丽华,李素水,孙志刚,等.精神分裂症认知障碍和功能预后关系的纵向研究进展[J].国际精神病学杂志,2015,42(5):47-51.
[4]梅力,易正辉.精神分裂症伴发代谢综合征的防治研究进展[J].中国神经精神疾病杂志,2014,40(7):443-446.
[5]董佳丽,常艳玲,黄震,等.新型非典型抗精神病药物的应用及研究进展[J].上海医药,2015,36(7):53-56.
[6]司天梅,杨建中,舒良,等.阳性和阴性症状量表(PANSS,中文版)的信、效度研究[J].中国心理卫生杂志,2004,18(1):45-47.
[7]Stephen R.Marder,Wayne Fenton.Measurement and treatment research to improve cognition in schizophrenia:NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia[J].Schizophrenia Research,2004,72(1):5-9.
[8]Morosini PL,Magliano L,Brambilla L,et al.Development,reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale(SOFAS)to assess routine social funtioning[J].Acta Psychiatrica Scandinavica,2000,101(4):323-329.
[9]严峰,陆峥,周卉.精神分裂症与认知功能障碍及其生物学基础研究[J].世界临床药物,2013,34(11):693-697.
[10]左赛,Linda K.BYRNE,彭代辉,等.症状严重程度比认知缺损更与精神分裂症住院患者的社会功能状况密切相关(英文)[J].上海精神医学,2012,24(2):83-90.
[11]朱叶,方菁,张蓓,等.精神分裂症社会认知功能缺陷的功能影像研究[J].中国临床心理学杂志,2014,22(2):232-239.
[12]何宗岭,黄吉林,李涛,等.首发精神分裂症患者治疗前后认知功能损害的比较[J].中国神经精神疾病杂志,2013,39(7):411-415.
[13]孟美玲,李清伟,盛建华,等.阿立哌唑治疗抗精神病药物所致高催乳素血症的研究进展[J].精神医学杂志,2015,28(3):232-234.
[14]Hikaru H,Yoshimura R,Katsuki A,et al.The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients[J].Journal of Psychiatric Research,2012,46(6):757-761.
[15]王汝展.精神类药物基因组学研究进展[J].精神医学杂志,2016,29(1):47-52.
[16]Riedel M,Schennech-Wolff R,Musil R.Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole,olanzapine,quetiapine and risperidone[J].Human Psychopharmacology,2010,25(2):116-125.
[17]梁静文,许瑞环.精神分裂症患者认知功能障碍的相关基因研究进展[J].精神医学杂志,2017,30(6):465-471.
[18]Ahmed El-Missiry,Amira Elbatrawy,Marwa El Missiry,et al.Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia[J].Journal of Psychiatric Research,2015,70(1):S97-S98.
[19]罗爱军,陈哨,单超.精神分裂症患者认知功能损害特点及非药物治疗方法的研究进展[J].河北医药,2018,40(17):2683-2687.
[20]何孔亮,刘晓林,韦邦贵,等.阿立哌唑与利培酮对精神分裂症后抑郁患者疗效与执行功能的影响[J].安徽医药,2015,19(4):772-774.